The second-highest doses of the drug MK-859 lowered "bad" LDL cholesterol by 40%, while increasing the patient's "good" HDL cholesterol by a very impressive 139%. When the highest dose of MRK-859 was combined with Lipitor, the LDL cholesterol dropped even more -- to 68% of the starting level.
Most importantly, Merck didn't see the rise in blood pressure that occurs with Pfizer's torcetrapib. Investors should be cautiously optimistic about the results, but only a much larger and longer phase 3 trial will tell for certain that there are no side effects big enough to derail this blockbuster.
Merck is taking a multifaceted approach to finding a blockbuster that increases HDL levels. The only drug on the market that substantially increases HDL, niacin, has the bad side effect of turning patients flush. The company is waiting on an FDA decision over its CORDAPTIVE drug, which is a combination of its extended-release niacin and a flushing pathway inhibitor. If MK-859 is ever approved, it would compete with CORDAPTIVE, as well as with Abbott Laboratories'
With Zocor already facing generic competition, Merck is trying to expand its cholesterol-fighting dynasty beyond Zetia and Vytorin (since it has to share profits for both with Schering-Plough
More from The Motley Fool
Why 2017 Was a Year to Forget for Merck & Co. Inc.
Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.
These 3 Stocks Just Raised Their Dividends
Shareholders of Walt Disney, Merck, and McCormick are getting some gifts in advance of the holiday season.
3 Stocks That Cut Bigger Checks Than PepsiCo
Pepsi is a fantastic business with a healthy dividend. But your quarterly check will be even larger if you invest in these three companies.